Drugs / VE416
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03936998 | Jun 2019 → Nov 2023 overdue | food allergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VE416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936998 ↗ |
| Modality | Other / unclassified | “VE416 is a consortium of commensal, or "friendly", dormant (inactive) bacteria given in a capsule.” NCT03936998 ↗ |
| Route | Oral | “VE416 PO QD x 6 weeks” NCT03936998 ↗ |